Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Freedom Finance and Binance Join Forces in Digital Assets 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
DURHAM, N.C., May 02, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 8:40 a.m. ET at the InterContinental Boston Hotel.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
